- |||||||||| Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open. (Pubmed Central) - Apr 15, 2025
Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) + nivolumab (anti-PD-1) in untreated, metastatic melanoma has achieved a ten-year melanoma-specific survival of 52%...Addition of ipilimumab, relatlimab (anti-LAG3), or lenvatinib (VEGFR TKI) has minimal to modest efficacy...Recently, personalized, autologous tumor-infiltrating lymphocyte therapy has become a US Food and Drug Administration-approved second-line option; lifileucel demonstrates durable response (approximately 30%) in heavily pretreated, metastatic melanoma...As a therapy which is limited to patients who are HLA-A*02:01, T-cell receptor (TCR) engineered T cells (TCR-T) iterates on personalized adoptive cell transfer, and immune mobilizing monoclonal TCRs against cancer are CD3 bispecifics that bind glycoprotein 100 (tebentafusp, approved for metastatic uveal melanoma) or PRAME to activate T cells...ICI may be given with modified immunosuppression in patients with autoimmune disease or previous organ transplantation. Cumulative data support safe administration in older patients and in ICI rechallenge for patients with previous irAE.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial completion date: CA209-6D9: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (clinicaltrials.gov) - Mar 27, 2025 P1, N=1, Completed, Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jun 2030 Active, not recruiting --> Completed | N=16 --> 1 | Trial completion date: Jun 2025 --> Aug 2024
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Treatment of metastatic melanoma with anti-PD-1 and anti-LAG-3 in a kidney transplant recipient. (Pubmed Central) - Mar 27, 2025 LAG-3 expression was notably positive in the renal graft, but negative in the metastatic melanoma tumor tissue. Although the outcome resulted in rapid renal graft rejection, this underscores the need for further research into LAG-3's dual role in cancer therapy and allograft rejection in organ transplant recipients.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Microscopic colitis - rare events secondary to immune checkpoint inhibitors therapy (Section 34; Poster Board No: 15) - Mar 25, 2025 - Abstract #AACR2025AACR_7771; MC is suspected to result from increased immune activity in the gut mucosa. It can develop following ICIs therapy and presents with severe symptoms, often requiring hospitalization, steroids, and other immunomodulators.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma (Section 28; Poster Board No: 18) - Mar 25, 2025 - Abstract #AACR2025AACR_7718; We leveraged cutting-edge spatial -omics technologies and novel computational methods to resolve the immunologic hallmarks of NICB response in metastatic melanoma. We believe our approach will usher in a new paradigm for the investigation of other cancer biospecimens in the new era of standard of care neoadjuvant immunotherapy.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Unravelling the mechanisms of resistance and hyperprogression of renal medullary carcinoma to immune checkpoint therapy (Section 28; Poster Board No: 12) - Mar 25, 2025 - Abstract #AACR2025AACR_2818; P2 IACS16898 treatment significantly reduced the expression of myeloid-associated markers on GFP+ tumor cells. Our study not only elucidates a novel mechanism of resistance and hyperprogression to PD1 plus either CTLA4 or LAG3 inhibition in SMARCB1-deficient cancers but also provides a foundation for targeting oncogenic and resistance pathways in RMC treated with distinct immunotherapy regimens.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade. (Pubmed Central) - Mar 25, 2025 This case provides the first evidence of dual PD-1/LAG-3 blockade inducing an immune response in CDS. The favorable response and tolerability observed in this patient highlight the potential of dual ICB as a therapeutic option in CDS that merits further investigation.
- |||||||||| IMA203 / Immatics
Enrollment open: SUPRAME-ACTengine (clinicaltrials.gov) - Jan 17, 2025 P3, N=360, Recruiting, Given the potential severity of myocarditis, myositis, and myasthenia gravis-like syndrome, immediate corticosteroid treatment is recommended upon suspicion, without awaiting a confirmed diagnosis. Not yet recruiting --> Recruiting
- |||||||||| IMA203 / Immatics
New P3 trial: SUPRAME-ACTengine (clinicaltrials.gov) - Dec 19, 2024 P3, N=360, Not yet recruiting,
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Adverse events, Real-world evidence, Real-world, Metastases: Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma. (Pubmed Central) - Dec 5, 2024 However, further research and longer follow-up periods are needed to compare it with previous treatments and validate its long-term effectiveness and safety. Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation.
- |||||||||| relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Dec 5, 2024 P2, N=27, Active, not recruiting, Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation. Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2024
- |||||||||| Review, Journal, Checkpoint inhibition: Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy. (Pubmed Central) - Nov 15, 2024
Despite clinical improvements with immunomodulatory therapy, with corticosteroids the mainstay of treatment, mortality remains high, particularly in those with associated myocarditis or respiratory failure requiring intubation, where mortality occurs in up to 50%. ICI withdrawal can lead to cancer progression and death, highlighting a need for improved approaches to ICI rechallenge, performed in limited patients with variable success to date.
|